NCT03895749View on ClinicalTrials.gov

Effect of a Nitric Oxide Supplementation Product on Endothelial Dysfunction and Prehypertensive Adults

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

February 1, 2018

Study Completion Date

April 18, 2018

Conditions
Hypertension
Interventions
DIETARY_SUPPLEMENT

NEO40 Daily

Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.

Trial Locations (1)

37205

Hypertension Institute, Nashville

Sponsors

Collaborators (1)

Neogenis Laboratories
All Listed Sponsors
collaborator

Neogenis Laboratories

OTHER

lead

Hypertension Institute, Nashville

OTHER

NCT03895749 - Effect of a Nitric Oxide Supplementation Product on Endothelial Dysfunction and Prehypertensive Adults | Biotech Hunter | Biotech Hunter